Cytek Biosciences (CTKB) Free Cash Flow (2020 - 2026)

Cytek Biosciences has reported Free Cash Flow for 7 years, with the latest figure at -$4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 315.2% year-over-year to -$4.0 million; the trailing twelve-month figure through Mar 2026 stood at -$7.9 million (down 138.35% YoY), and the FY2025 full-year result was -$4.8 million, down 119.11% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$4.0 million, down from -$815000.0 in the prior quarter.
• The five-year high for Free Cash Flow was $14.7 million in Q3 2024, with the low at -$8.9 million in Q2 2022.
• Historically, Free Cash Flow has averaged $185764.7 across 5 years, with a median of -$974000.0 in 2025.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 729.24% — and 2024, when it surged 442.44%.
• Cytek Biosciences' Free Cash Flow stood at $4.8 million in 2022, then gained by 2.46% to $5.0 million in 2023, then tumbled by 61.31% to $1.9 million in 2024, then slumped by 142.47% to -$815000.0 in 2025, then plunged by 396.2% to -$4.0 million in 2026.
• The last three Free Cash Flow figures came in at -$4.0 million (Q1 2026), -$815000.0 (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.